Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CRSP 
Crispr Therapeutics AG (CRSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: CRSP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
28 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $81.67
Year Target Price $81.67
| 12 | Strong Buy |
| 5 | Buy |
| 10 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.16% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.10B USD | Price to earnings Ratio - | 1Y Target Price 81.75 |
Price to earnings Ratio - | 1Y Target Price 81.75 | ||
Volume (30-day avg) - | Beta 1.74 | 52 Weeks Range 30.04 - 63.68 | Updated Date 06/29/2025 |
52 Weeks Range 30.04 - 63.68 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.49 |
Earnings Date
Report Date 2025-05-30 | When Before Market | Estimate -1.2768 | Actual -1.58 |
Profitability
Profit Margin - | Operating Margin (TTM) -17158.84% |
Management Effectiveness
Return on Assets (TTM) -12.88% | Return on Equity (TTM) -19.71% |
Valuation
Trailing PE - | Forward PE 23.36 | Enterprise Value 2465484353 | Price to Sales(TTM) 108.86 |
Enterprise Value 2465484353 | Price to Sales(TTM) 108.86 | ||
Enterprise Value to Revenue 70.44 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 86363696 | Shares Floating 85970729 |
Shares Outstanding 86363696 | Shares Floating 85970729 | ||
Percent Insiders 1.76 | Percent Institutions 76.58 |
Analyst Ratings
Rating 3.96 | Target Price 81.67 | Buy 5 | Strong Buy 12 |
Buy 5 | Strong Buy 12 | ||
Hold 10 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Crispr Therapeutics AG
Company Overview
History and Background
CRISPR Therapeutics AG was founded in 2013 by Emmanuelle Charpentier, Rodger Novak, Shaun Foy, and Virginijus u0160iku0161nys, and focuses on developing gene-based medicines using its CRISPR/Cas9 platform. It has evolved from a research-focused entity to a clinical-stage biotechnology company with multiple ongoing clinical trials.
Core Business Areas
- Gene Editing Therapies: Development and commercialization of gene-edited cell therapies and in vivo therapies for various diseases.
- Research and Development: Ongoing research to expand the CRISPR/Cas9 platform and develop new therapeutic applications.
- Allogeneic Cell Therapies: Focus on developing off-the-shelf CAR-T cell therapies for cancer treatment.
Leadership and Structure
Samarth Kulkarni serves as the CEO. The company operates with a structured research and development team, clinical trial division, and corporate operations team.
Top Products and Market Share
Key Offerings
- Exagamglogene Autotemcel (exa-cel) - Casgevy: CRISPR-based therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Approved in multiple regions including the UK and US. Competitors include bluebird bio's Zynteglo and Lyfgenia, as well as Vertex Pharmaceuticals (partnered with Crispr Therapeutics) in this indication. Market share is emerging as the product launches.
- CTX110: Allogeneic CAR-T cell therapy targeting CD19-positive malignancies. Currently in clinical trials. Competitors include Kite Pharma (Gilead), Novartis, and other CAR-T therapy developers. Clinical trial data will determine eventual market share.
- CTX130: Allogeneic CAR-T cell therapy targeting CD30-positive malignancies. Currently in clinical trials for T-cell lymphomas. Competitors include Seagen and other developers of therapies for T-cell lymphomas. Clinical trial data will determine eventual market share.
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, driven by advances in CRISPR technology and increasing investment in gene-based therapies. Significant growth is expected in the coming years.
Positioning
CRISPR Therapeutics is a leading player in the gene editing space, particularly with the approval of Casgevy. The company is positioned to capture a significant share of the market for gene therapies, especially for genetic blood disorders.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to reach billions of dollars. CRISPR Therapeutics is well-positioned to address a substantial portion of this market through its SCD and TDT therapies, and its CAR-T cell therapy programs.
Upturn SWOT Analysis
Strengths
- Pioneering CRISPR/Cas9 technology
- Strong intellectual property portfolio
- Strategic partnerships with leading pharmaceutical companies (e.g., Vertex)
- Approved gene therapy product (Casgevy)
- Robust pipeline of clinical-stage programs
Weaknesses
- High development costs associated with gene therapies
- Regulatory uncertainty surrounding gene editing technologies
- Potential for off-target effects or other safety concerns
- Dependence on key partnerships for commercialization
- Manufacturing complexities and scalability challenges
Opportunities
- Expansion of CRISPR/Cas9 platform to new therapeutic areas
- Advancement of CAR-T cell therapy programs
- Potential for curative treatments for genetic diseases
- Increased investment in gene editing technologies
- Strategic collaborations with biotech and pharmaceutical companies
Threats
- Competition from other gene editing companies
- Patent disputes and intellectual property challenges
- Adverse clinical trial results
- Reimbursement challenges for expensive gene therapies
- Ethical concerns surrounding gene editing
Competitors and Market Share
Key Competitors
- EDIT
- BEAM
- NTLA
Competitive Landscape
CRISPR Therapeutics is a leading player in the gene editing space. Its competitive advantages include its pioneering CRISPR/Cas9 technology, strong intellectual property portfolio, and strategic partnerships. The company faces competition from other gene editing companies, including Editas Medicine, Beam Therapeutics, and Intellia Therapeutics.
Growth Trajectory and Initiatives
Historical Growth: CRISPR Therapeutics' growth has been driven by advances in its clinical programs and strategic partnerships. The company has experienced significant growth in its market capitalization and research and development activities.
Future Projections: Future growth is projected to be driven by the commercialization of Casgevy, the advancement of its CAR-T cell therapy programs, and the expansion of its CRISPR/Cas9 platform to new therapeutic areas.
Recent Initiatives: Recent initiatives include the FDA approval of Casgevy, expansion of clinical trials for CTX110 and CTX130, and continued investment in research and development.
Summary
CRISPR Therapeutics is a leading gene editing company with a promising future, particularly with the approval of Casgevy. Its strong technology platform and strategic partnerships are key strengths. Challenges include regulatory hurdles, competition, and the high cost of gene therapy development. Further clinical trial success will be crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is approximate and may vary depending on the source. Financial data is not real-time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crispr Therapeutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-10-19 | CEO & Chairman Dr. Samarth Kulkarni Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://www.crisprtx.com |
Full time employees 393 | Website https://www.crisprtx.com | ||
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.